FastWave: The Next Generation of
Intravascular Lithotripsy (IVL)
Led by a powerhouse team of proven medtech entrepreneurs, we’re developing two differentiated IVL energy systems to advance the treatment of calcific disease.
FastWave: The Next Generation of Intravascular Lithotripsy (IVL)
Led by a powerhouse team of proven medtech entrepreneurs, we’re developing two differentiated IVL energy systems to advance the treatment of calcific disease.
FastWave: The Next Generation of Intravascular Lithotripsy (IVL)
Led by a powerhouse team of proven medtech entrepreneurs, we’re developing two differentiated IVL energy systems to advance the treatment of calcific disease.
Lethal but Treatable: Coronary Artery Disease (CAD) and Peripheral Artery Disease (PAD)
Lethal but Treatable: Coronary Artery Disease (CAD) and Peripheral Artery Disease (PAD)
Lethal but Treatable: Coronary Artery Disease (CAD) and Peripheral Artery Disease (PAD)
Calcium is Highly Prevalent in CAD and PAD
Calcium is Highly Prevalent in CAD and PAD
Calcium is Highly Prevalent in CAD and PAD
Calcific plaque, which is prevalent in about 30% of CAD patients, resists vessel expansion, making it difficult to treat with traditional interventional modalities.
Calcific plaque, which is prevalent in about 30% of CAD patients, resists vessel expansion, making it difficult to treat with traditional interventional modalities.
We continue to encounter coronary and peripheral disease complicated by severe calcium, presenting a significant therapeutic challenge when employing interventional tools
Dr. Amir Kaki
Interventional Cardiologist
We continue to encounter coronary and peripheral disease complicated by severe calcium, presenting a significant therapeutic challenge when employing interventional tools
Dr. Amir Kaki
Interventional Cardiologist
We continue to encounter coronary and peripheral disease complicated by severe calcium, presenting a significant therapeutic challenge when employing interventional tools
Dr. Amir Kaki
Interventional Cardiologist
IVL Has Been Rapidly Adopted Globally for Calcific Disease Treatment
IVL Has Been Rapidly Adopted Globally for Calcific Disease Treatment
IVL Has Been Rapidly Adopted Globally for Calcific Disease Treatment
The utilization of IVL for percutaneous coronary interventions is expected to grow at a 49% annual compounded rate due to its ease of use, favorable safety profile, and exceptional therapeutic efficacy.
The utilization of IVL for percutaneous coronary interventions is expected to grow at a 49% annual compounded rate due to its ease of use, favorable safety profile, and exceptional therapeutic efficacy.
FastWave is Empowering Physicians with Advanced IVL Technology
FastWave is Empowering Physicians with Advanced IVL Technology
FastWave is Empowering Physicians with Advanced IVL Technology
Our focus is clear: build upon the established success of IVL technology to enable interventionalists to deliver improved treatments, ensuring better outcomes for their patients.
Our focus is clear: build upon the established success of IVL technology to enable interventionalists to deliver improved treatments, ensuring better outcomes for their patients.
Our focus is clear: build upon the established success of IVL technology to enable interventionalists to deliver improved treatments, ensuring better outcomes for their patients.
FastWave’s Differentiated IVL Technology
FastWave’s Differentiated IVL Technology
Successful First-in-Human (FIH) Study
Successful First-in-Human (FIH) Study
Successful First-in-Human (FIH) Study
In our FIH study for PAD, we successfully treated 9 limbs across 8 patients with 100% lesions crossed with a mean residual diameter stenosis of only 5.5%, or a 93% reduction from baseline, indicating an almost complete resolution of blockages.
In our FIH study for PAD, we successfully treated 9 limbs across 8 patients with 100% lesions crossed with a mean residual diameter stenosis of only 5.5%, or a 93% reduction from baseline, indicating an almost complete resolution of blockages.
Pre-FastWave IVL Pulsing
Pre-FastWave IVL Pulsing
Pre-FastWave IVL Pulsing
Procedural Info
Procedural Info
Investigators
Investigators
Drs. Miguel Montero-Banker, Venkatesh Ramaiah, and Antonio Muñoa
Drs. Miguel Montero-Banker, Venkatesh Ramaiah, and Antonio Muñoa
Location
Location
San Lucas Hospital, Chiapas, Mexico
San Lucas Hospital, Chiapas, Mexico
Dates
Dates
January 11-12, 2024
January 11-12, 2024
Post-FastWave IVL Pulsing
Post-FastWave IVL Pulsing
Post-FastWave IVL Pulsing
Procedural Info
Procedural Info
9 successfully treated limbs across 8 patients
9 successfully treated limbs across 8 patients
100% of lesions crossed, including 3 CTOs
100% of lesions crossed, including 3 CTOs
Post-treatment mean residual diameter stenosis of 5.5%
Post-treatment mean residual diameter stenosis of 5.5%
0% AEs with no balloon ruptures
0% AEs with no balloon ruptures
FastWave is Advancing at an Unparalleled Pace
FastWave is Advancing at an Unparalleled Pace
FastWave is Advancing at an Unparalleled Pace
February 2021
February 2021
FastWave established as a stand-alone Delaware C-corp.
FastWave established as a stand-alone Delaware C-corp.
FastWave established as a stand-alone Delaware C-corp.
August 2021
August 2021
FastWave raises $12M Series A round of financing.
FastWave raises $12M Series A round of financing.
FastWave raises $12M Series A round of financing.
November 2022
November 2022
USPTO grants FastWave its first utility patent within 6 months of filing.
USPTO grants FastWave its first utility patent within 6 months of filing.
USPTO grants FastWave its first utility patent within 6 months of filing.
April 2023
April 2023
USPTO grants FastWave its second IVL utility patent.
USPTO grants FastWave its second IVL utility patent.
USPTO grants FastWave its second IVL utility patent.
June 2023
June 2023
FastWave closes oversubscribed private financing round within a few weeks.
FastWave closes oversubscribed private financing round within a few weeks.
FastWave closes oversubscribed private financing round within a few weeks.
January 2024
January 2024
FastWave completes enrollment for the first-in-human study of its peripheral IVL system.
FastWave completes enrollment for the first-in-human study of its peripheral IVL system.
FastWave completes enrollment for the first-in-human study of its peripheral IVL system.
See How You Can Invest in FastWave
We oversubscribed our last round of financing in just a few weeks, so don’t miss out on the next opportunity to invest.
IVL is an impressive therapy with an attractive market and I’m very excited about FastWave’s prospects.
Dr. Puneet Khanna
Interventional Cardiologist & Medtech Investor
See How You Can Invest in FastWave
We oversubscribed our last round of financing in just a few weeks, so don’t miss out on the next opportunity to invest.
IVL is an impressive therapy with an attractive market and I’m very excited about FastWave’s prospects.
Dr. Puneet Khanna
Interventional Cardiologist & Medtech Investor
See How You Can Invest in FastWave
We oversubscribed our last round of financing in just a few weeks, so don’t miss out on the next opportunity to invest.
IVL is an impressive therapy with an attractive market and I’m very excited about FastWave’s prospects.
Dr. Puneet Khanna
Interventional Cardiologist & Medtech Investor
